About Us

Our mission is to bring cleverly-designed medicine to patients with the most difficult to treat cancers, immune disorders and infectious diseases.

Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing ITK inhibition as a new approach to immunotherapy. Our mission is to bring cleverly-designed medicine to patients with difficult to treat cancers and immune diseases.

Our seasoned team of biopharma industry leaders are dedicated to developing new medicines for patients in need. Their successful track record of discovering, developing and commercializing innovative therapies for patients with serious diseases includes inventors and scientists who developed the anti-cancer and auto-immune disease medicines, Rituxan (rituximab), Imbruvica (ibrutinib) and Zelboraf (vemurafenib). The development of ITK inhibition, which targets the modulation of T cells, is a significant opportunity that parallels Rituxan (targeting CD20) and Imbruvica (targeting BTK), both of which modulate B cells.

Founded in 2014, Corvus has developed a deep pipeline of potentially breakthrough investigational medicines designed to be potent, selective and convenient to administer. The Company is focused on the advancement of its ITK inhibitor and is working with partners to advance its other clinical stage programs.

We believe in putting patients first. With that in mind, we report our preclinical and clinical data promptly and frequently at major scientific meetings, so our research can be used by others to advance medicine for the benefit of patients.

Our Science

We are developing ITK inhibition as a new approach to immunotherapy for cancer and immune diseases

Join Our Team

Contribute your talent, expertise and desire to learn here at Corvus, where you can help improve the lives of people with cancer, immune disorders and infectious diseases